Discovery/R&D

41. Antibodies For Severe Allergies With IgGenix's Jessica Grossman, M.D. 4/4/2022

    In this wide-ranging discussion, IgGenix CEO Jessica Grossman, M.D. discusses the application of and market opportunity for antibody therapy for severe allergies, the gender gap in the biopharma c-suite, why women work harder than men, what it means to be a female biopharma leader, and IgGenix's approach at isolating and re-engineering allergen-specific IgE antibodies into IgG antibodies designed to alleviate — and possibly prevent — allergic cascade.

42. Oncology Discovery Advances With AbbVie's Steve Davidsen, Ph.D. 10/25/2022

    AbbVie VP of Oncology Discovery Research Steve Davidsen, Ph.D. is a living, breathing timeline of the company's cancer research and development efforts. He got his start with the company— Abbott at the time— way back in 1986. As such, he's charted the adoption of multiple advanced technologies that have contributed to the realization of dozens of molecular weapons in the fight against cancer. On this episode of the Business of Biotech, Dr. Davidsen shares the latest on AbbVie's adoption of computational biology and how it's contributing to discovery and development efficiencies, why he's an AbbVie "lifer," how he manages and motivates a large team of research scientists, and a whole lot more.

43. Celyad CEO Filippo Petti On In-House Allogeneic Cell Therapy Manufacturing 2/8/2021

    Join Matt Pillar and Erin Harris as we catch up with Celyad Oncology chief Filippo Petti on his company's differentiated approach to the discovery and development of allogeneic CAR-T cell therapy candidates for the treatment of cancer. Petti shares the technology and how the company intends to scale in-house manufacturing in its Belgium-based manufacturing facility.

44. Building A DNA Delivery System With Poseida Tx CEO Eric Ostertag, M.D., Ph.D. 9/27/2021

    Eric Ostertag, M.D., Ph.D., wanted to launch a biotech. When University of Pennsylvania department heads said no to a licensing deal for lack of a CEO, Dr. Ostertag convinced them he could run the company. Many bold moves later, Dr. Ostertag is founder and CEO at Poseida Therapeutics, a company that's doing things never seen before in the field of CAR T-cell and gene therapies for multiple myeloma and prostate cancer. On this week's episode of The Business of Biotech, Dr. Ostertag gives us a tour of the architecture supporting Poseida's unique 3-tiered development and manufacturing platform.

45. Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch 4/28/2024

    As if Orna Therapeutics' CEO, Thomas Barnes, isn't enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O", RNA and why it holds great potential to best linear RNA constructs, the novel, platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy, viral vector and lipid nanoparticle complexity, and a whole lot more.

46. Expanding The Proteome with ProFound's John Lepore, M.D. 7/28/2024

    Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question:  What if more RNAs were being translated into proteins? Answering that question took ProFound deep into the translatome.

47. Pragmatic Computational Biology with Andrew Satz 9/20/2023

    This week's guest on the Business of Biotech, EVQLV's Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say they're doing it really aren't, and the one who really are aren't talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware?

48. COO Liftoff With Rocket Pharmaceuticals' Kinnari Patel, PharmD 7/12/2023

    Chief Operating Officer is arguably the toughest job in the emerging biopharma C-suite. HR, CMC, regulatory affairs, legal, PR, you name it, the COO touches it, and practically everything rolls up to her. This week's episode of the Business of Biotech brings us to a president and COO who's also a mom, a volunteer, and an advocate for diversity and equality in biopharma. That advocacy isn't just lip service, by the way. Here, Rocket Pharmaceuticals' Kinnari Patel, PharmD, shares on the real, practical, replicable steps Rocket takes to build a diverse and equitable work environment, how the fruits of that effort have proven important to the company's success, and where Rocket is taking its high-flying gene therapy act next.

    Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

49. Precision Radiopharmaceuticals with Ratio's Jack Hoppin, Ph.D. 2/21/2024

    Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely related and necessary companion diagnostic arena.

50. Med Device Meets Biopharma With OncoSec's Dan O'Connor, J.D. 5/17/2021

    OncoSec CEO & Director Dan O'Connor, J.D. joins the Business of Biotech to discuss his company's development of proprietary application and injection technologies for direct delivery of its pipeline of immunotherapeutic candidates and combination therapies into the tumor environment. O'Connor shares leadership lessons gleaned from his service as a Captain in the United States Marine Corps during Operation Desert Shield, and how he's applied those lessons as his company charts the manufacturing and regulatory challenges along its unique development timeline.